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Foreword
Education plays a critical role in preparing a competent health workforce to meet the healthcare needs of the public, and 
pharmacists have an essential role in ensuring the effective and responsible use of medicines. Pharmacists are able to monitor 
medicines use, and support patients to adhere to medication regimens and to use medicines responsibly, and pharmaceutical 
scientists are able to develop novel medicines and therapeutic strategies. The International Pharmaceutical Federation (FIP) 
is dedicated to advancing pharmaceutical education worldwide, and has led a wide range of activities and initiatives geared 
towards improving medicines and their use. 
The FIP Academic Pharmacy Section (AcPS) has, since its inception in 1972, focused on promoting pharmaceutical education 
worldwide and has facilitated many academically oriented activities. These efforts intensified in 2008 through the release of FIP’s 
Vision 2020 and the formation of the Pharmacy Education Taskforce (PET) — a collaboration between FIP, the World Health Orga-
nization (WHO) and the United Nations Educational, Scientific and Cultural Organization (UNESCO). The PET led to the develop-
ment of a comprehensive programme through a dedicated structure called FIP Education (FIPEd), and its role and function were 
formally introduced into the governing FIP statutes in 2016. 
FIPEd integrates extensive networks such as schools of pharmacy and pharmaceutical sciences (represented by their deans 
through Academic Institutional Membership; AIM), experts in specific education-related fields (gathered in domains comprising 
the Education Development Team), and educators gathered in the AcPS. FIPEd has a major role in leading the transformation and 
scaling of pharmaceutical education in the context of workforce development, in collaboration with professional organisations 
and representative global organisations such as the WHO and UNESCO. 
In the 2012 FIP Centennial Declaration, pharmacists and pharmaceutical scientists accepted responsibility and accountability 
for improving global health and patient outcomes by improving the development, distribution and responsible use of medi-
cines. Achieving this goal requires a workforce of pharmacists and pharmaceutical scientists who are sufficient in number and 
are competent to deliver the full range of pharmaceutical services and to meet the challenges facing global health and patient 
care. Creating and adopting a globally shared vision that can guide country-level initiatives to develop such a pharmaceutical 
workforce became a priority. 
FIPEd adopted a seven-pillar action plan (2013–2018) aimed at stimulating and facilitating the transformation of workforce edu-
cation. The first pillar was planning a Global Conference on Pharmacy and Pharmaceutical Sciences Education. The goals of this 
conference were to gather policymakers, educational leaders and regulators from around the world to reach consensus about 
an envisioned future for pharmaceutical education. This plan became a reality when FIP hosted this unique on 7 and 8 November 
2016, in Nanjing, China. 
The pathway of FIP’s commitment to advancing pharmaceutical education is best described as a series of chapters. The first 
chapter was the Vision 2020 document when FIP made explicit its commitment to increasing its role in reforming pharmaceuti-
cal education. Following this decision, the second chapter included three important events: the creation of the PET, the signing 
of the Centennial Declaration at the 2012 FIP Centennial Congress in Amsterdam, Netherlands, and the establishment of FIPEd. 
The global conference in Nanjing represents the third chapter of FIP’s efforts and journey towards advancing education. At this 
event, FIP led the creation of a clear roadmap on which the international community can rely to advance education and training 
through a globally shared vision. With the support of FIP, the next chapters will require the active participation of all pharma-
cists, pharmaceutical scientists and pharmacy stakeholders around the world to turn this global vision into actions.
               
              
Prof. Sang Guowei
Conference co-chair and President, 
Chinese Pharmaceutical Association
Prof. Philip Schneider, 
Conference co-chair and Vice President, 
International Pharmaceutical Federation
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3. Calls for action
To translate these outcomes into actions, FIP calls on 
leaders in pharmacy practice, pharmaceutical sciences, 
and pharmaceutical education, governments and other key 
stakeholders to:
3.1 Support and advocate the implementation of the 
global Vision, PWDGs and the Nanjing Statements.
3.2 Engage in a national dialogue with key stakeholders 
(including governments) to analyse the current 
workforce profile and identify the needs for change; 
review or develop a strategy for the pharmaceutical 
workforce, guided by the conclusions of the global 
conference.
3.3 Prioritize the adoption of the PWDGs in the context 
of their national strategies on health and workforce 
development.
3.4 Report back to FIP on how have they have 
implemented the conclusions of the conference.
1. Key messages
1.1 The continued development of pharmacy services 
and the pharmaceutical sciences relies on a well 
educated, competent, sufficient and well distributed 
pharmaceutical workforce. 
1.2 There is no workforce without education. It is 
fundamental for the international community to agree 
on how pharmaceutical workforce competency is 
developed and assured through initial and subsequent 
professional education. 
1.3 The concept of a continuously competent workforce is 
of fundamental interest for professional leadership 
bodies and stakeholders. 
1.4 As FIP member organisations drive the development 
of the profession at the national level, they should 
always consider encompassing an education 
component [initial education and Continuing 
Professional Development (CPD)/Continuing Education 
(CE)] into their strategies. 
1.5 FIP brought together global health and pharmacy 
leaders from across the world to set the future 
milestones for pharmaceutical education in the 
context of workforce development during an 
exceptional event, which took place in Nanjing, China, 
on 7 and 8 November 2016: the Global Conference on 
Pharmacy and Pharmaceutical Sciences Education — 
"Creating a global vision for a global workforce".
1.6 The conference set the future milestones for 
education and workforce development of 
pharmacists and pharmaceutical scientists, and 
created a global vision for transformative pharmacy 
and pharmaceutical sciences education.
2. Principal outcomes
Following extensive consultation, three milestone 
documents were presented and adopted at the global 
conference. Participants at the conference were able to 
influence and contribute to them. These are:
2.1 A Global Vision for Education and Workforce that 
provides a description of the future directions of 
our profession and how education can support the 
evolution of science and practice. 
2.2 A set of 13 Pharmaceutical Workforce Development 
Goals (PWDGs) which aim to facilitate the 
implementation of the global vision through a series of 
measurable, feasible and tangible goals. 
2.3 A set of 67 statements on Pharmacy and 
Pharmaceutical Sciences Education ("the Nanjing 
Statements") that describe an envisioned future for 
education, to enable the enhancement of professional 
education standards worldwide.
EXECUTIVE SUMMARY
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Investing in the development of healthcare professionals’ 
education and training has garnered special attention as 
reflected by recent global policy activity on the matter. A 
global commission on the Education of Health Professionals 
for the 21st Century was formed in 2010.12 It was charged 
with driving educational reforms to produce healthcare 
professionals who are more equipped and better prepared 
to meet current and future needs, and to face existing and 
emerging health challenges.13 Driven by the commission’s 
efforts, the WHO produced its first guidelines on health 
workforce education in 2013. These evidence-based guidelines, 
presented in a report titled “Transforming and Scaling Up 
Health Professionals’ Education and Training”, emphasise the 
importance of scaling-up the health workforce’s educational 
and training systems such that they will adequately meet 
population needs.14 
Just as no healthcare system can function without a health 
workforce, there can be no real health workforce without 
proper education and training. Developing health workers 
through scaling up their education and training is a critical 
determinant of health outcomes and service delivery, and the 
recent activity in global strategies and initiatives not only 
affirms this notion but also provides an unprecedented level 
of support to policy-makers and stakeholders to guide them 
on transforming and scaling up health workforce education 
and training. The future of health and the integrity of our 
health systems are closely intertwined with the capabilities 
and competencies of healthcare workers; and quality health 
service delivery depends on sustainably strengthening health 
workers and their capacities to meet complex population 
and health needs. Investing in the education, training and 
development of healthcare professions has therefore become 
a global imperative.
1.2 Why invest in the pharmaceutical 
workforce?
Medicines are vital in the prevention, diagnosis, treatment 
and cure of disease. Access to safe and effective medicines 
is a fundamental human right and a central pillar of any 
healthcare system.15 Medicines and medicines development, 
medicines management and the responsible use of medicines 
are vital components in improving the health of nations.16,17 
As medicine experts, the pharmaceutical workforceª is an 
integral part of the healthcare team that plays a key role 
in bettering health outcomes through optimising patients’ 
use of medicines.18 In many countries, pharmacists are the 
most accessible of all healthcare workers and as such are at 
the forefront of healthcare service delivery.19 Joint FIP/WHO 
1.1 Why focus on the health workforce?
The health workforce is at the core of every healthcare 
system, and healthcare delivery is impossible without human 
resources for health.1 Overcoming health system challenges 
and improving health outcomes depend on the availability, 
accessibility and quality of health workers.2,3 Human resources 
for health are facing significant challenges worldwide.4 Nearly 
all nations around the world face health systems constraints 
related to workforce issues spanning severe shortages, low 
accessibility, skill mix imbalances and inadequate education 
and training.5,6 According to the WHO, emerging health 
problems such as growing populations, changing disease 
patterns, and shifting economic trends will have varying 
effects around the world. As a result of these projected 
challenges, the WHO predicts that 40 million new healthcare 
sector jobs will be created in high- and middle-income nations 
by 2030, but developing nations will experience a shortage of 
about 18 million health workers.7
These challenges, coupled with the mounting evidence of the 
impact of health workforces on population health outcomes, 
have placed health workforce issues at the top of the global 
health agenda. The health workforce is a critical component 
of the post-2015 health development frameworks, notably the 
17 United Nations Sustainable Development Goals (SDGs).8 
Given that the projected workforce shortages in developing 
countries pose serious concerns with regard to meeting 
the health-related targets of the SDGs, especially when 
healthcare workers have been identified as essential agents 
of sustainable development,9 it is not surprising that one of 
the health targets under SDG 3 — “Ensure healthy lives and 
promote wellbeing for all at all ages” — refers specifically to 
the health workforce. It reads as follows:
“3.c Substantially increase health financing and the 
recruitment, development, training and retention of the 
health workforce in developing countries, especially in least 
developed countries and small island developing States.”
In supporting this target’s achievement, the WHO adopted 
a Global Human Resources for Health Strategy: Workforce 
2030 at the 2016 World Health Assembly. The strategy calls 
for swifter progress towards the SDGs and universal health 
coverage through ensuring equitable access to a competent 
health workforce.10 Additional political attention on the 
question of workforce was reached through the establishment 
of the United Nations High-Level Commission on Health 
Employment and Economic Growth. The commission’s main 
task was to propose actions to stimulate the creation of 
health sector jobs, with careful consideration being given 
to the needs of low- and lower middle-income nations. The 
commission launched its final report at the 2016 UN General 
Assembly; the report outlines a series of 10 recommendations 
to transform the health workforce in the context of the SDGs.11 
The report also finds that investing in health workers not only 
has a positive impact on employment rates and economic 
growth, but also results in remarkable improvements in health 
and population outcomes. 
PART 1
INTRODUCTION AND BACKGROUND
ª  - Pharmaceutical workforce , in this document, refers to the whole of 
the pharmacy related workforce (e.g. registered pharmacist practitioners, 
pharmaceutical scientists, pharmacy technicians and other pharmacy 
support workforce cadres, pre-service students/trainees) working in a 
diversity of settings (e.g., community, hospital, research and development, 
industry, military, regulatory, academia and other sectors) with a diversity 
of scopes of practice.
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in healthcare delivery, the roles of pharmacists are being 
constantly redefined. This is driving continuous change in 
competency and training requirements, but there is still 
variation and gaps in pharmaceutical education and the range 
of quality assurance systems. This could be partly due to the 
absence of a globally shared strategy that offers achievable 
and adaptable objectives that are implementable on a national 
level. Thus, providing a globally shared and sustainable 
roadmap for transforming pharmaceutical education and 
workforce development became a priority for FIP.
1.3 Why a global conference on education?
Investments in the health workforce are needed now more 
than ever, and putting forward strategies to guide and 
facilitate workforce development is a necessity. Achieving 
the targets set by the UN as part of the SDGs relies on the 
extent of workforce-centric improvements and development 
plans. Global strategies based on emerging evidence and 
best practices can inform and fuel more concerted and 
multi-stakeholder action on both national and international 
levels. The Global Strategy on Human Resources for 
Health: Workforce 2030 reaffirms the importance of the 
pharmaceutical workforce as part of the healthcare team 
and outlines target milestones and policy options that link 
investments in education to labour market dynamics and 
healthcare needs. Pharmaceutical education has always 
been a priority for FIP and is strategically considered in the 
context of the larger theme of pharmaceutical workforce 
development. FIP recognises that there can be no effective 
pharmaceutical services without an efficient workforce, 
and that there can be no efficient workforce without a solid 
foundation of education and training. 
Educational reform in the context of workforce development 
requires a sustainable and consensus-based roadmap. It 
is fundamental for the international community to agree 
on how pharmaceutical workforce competency is assured 
through initial and subsequent education. A globally shared 
vision has to be established so that pharmacists can accept 
responsibility and accountability for improving global 
health. The concept of a continuously competent workforce 
is of central interest for professional leadership bodies and 
professional stakeholders. As FIP member organisations drive 
the development of the profession to accommodate new 
services and roles, their strategies should always consider 
an educational component that covers both initial and 
continuing education. FIP provides a global platform to bring 
together pharmaceutical leaders from across the world to set 
the future milestones for pharmaceutical education in the 
context of workforce development. 
In supporting the implementation of the UN and WHO 
recommendations and policies and in line with FIPEd 
five-year action plan, FIP decided to address the development 
of future milestones for education and training by hosting 
a Global Conference on Pharmacy and Pharmaceutical 
Sciences Education. 
guidelines on good pharmacy practice were developed to set 
nationally accepted standards for the quality of pharmacy 
services and identified a number of key roles and functions 
expected from pharmacists.20 However, the capacity to meet 
these expectations, including delivering these pharmaceutical 
services, depends on having an assured, competent workforce 
and an integrated academic workforce to train sufficient 
numbers of new pharmacists and other support staff at both 
foundation and advanced levels. This, in part, explains why 
pharmacists have been recognised in the indicator selected 
by the UN to follow-up on the achievement of the health 
target 3.c focusing on health workforce; the measurement will 
include the density of pharmacists per population (in addition 
to physicians, nursing personnel, midwifery personnel and 
dentists).21
Evidence from FIPEd’ research projects and publications 
collectively calls for a clear and urgent need to invest in the 
capacity building of skilled medicines expertise who can 
meet the pharmaceutical health needs of populations around 
the world. Despite pharmacists being at the forefront of 
healthcare delivery, the global pharmaceutical workforce 
faces many challenges. The 2012 FIP Global Pharmacy 
Workforce Report described a number of problems facing 
pharmaceutical human resources around the world, mirroring 
the challenges faced by the wider global health workforce.22 
Access to pharmaceutical services in developing countries 
and regions, such as Africa, is hindered by the insufficient 
supply of well trained pharmacists. This carries implications 
for global inequalities in access to medicines and medicines 
expertise. The 2015 Global Pharmacy Workforce Intelligence 
Trends Report illustrates that while the past decade 
witnessed a general increase in workforce numbers around 
the world, some low-income regions and countries still have 
a disproportionately low number of pharmacists and a low 
capacity for delivering pharmacy services.23
Global variance in capacity is displayed not only in workforce 
numbers, but also in their education and training. Findings 
from the 2013 FIPEd Global Education Report indicate that 
the state of pharmaceutical education varies considerably 
between countries and regions, in terms of academic 
capacity, institutional infrastructure, and quality assurance 
mechanisms.24 Pharmacy educators continue to face 
challenges in meeting stakeholder requirements, and this is 
made more difficult in developing countries because of the 
lack of sufficient resources and expertise.25 Calls have been 
made for competency-driven curricular reform to bridge the 
gap between pharmaceutical education and given health 
needs. The FIP Global Competency Framework has been 
developed by FIPEd for this approach, and has been adapted 
and adopted by several countries for mapping country-specific 
needs.26 In addition, an adaptable quality assurance framework 
has been developed and adopted by FIP to support the 
institutional delivery of high quality education.27
Investing in transforming and scaling up pharmaceutical 
education is crucial for preparing a workforce that is able to 
adapt to new roles. In an era of rapidly accelerating changes 
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outcomes from a series of workshops on the second day, 
FIP plans to establish the tools and information needed to 
translate the key outcomes of the global conference into 
mechanisms applicable and meaningful at local 
(e.g., educational institutions), national and regional levels.
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The conference intended to make a significant contribution 
to improving global health outcomes by ensuring that there is 
a sufficient, well distributed and competent pharmaceutical 
workforce to meet the current and future needs in the 
development, distribution, and responsible use of medicines. 
The global conference was the first conference of its kind, 
and it aimed to meet the principles accepted in 2012 through 
the FIP Centennial Declaration and to reach agreement on 
how pharmaceutical workforce competence can be assured 
through education. Through the leadership role of FIP, 
pharmacy is the first health profession to play an active role in 
translating the WHO Global Strategy on Human Resources for 
Health into a professional context.
The global conference aimed to create dialogue and 
consensus among policy makers, educators, professional and 
scientific leaders, and regulators, to set the future milestones 
for education and workforce development strategies, 
activities and projects. The scope of the Conference was to 
address the education and developmental needs to create 
a competent pharmaceutical workforce, including initial 
education and training for pharmacists and pharmaceutical 
scientists. Continuing education and continuing professional 
development were also acknowledged as fundamental aspects 
of a competent workforce and are of central interest to both 
professional leadership bodies and professional stakeholders.
The objectives of the global conference were to:
1. Describe the current state of pharmacy and 
pharmaceutical sciences education globally; 
2. Define the envisioned education based on current 
and future needs for the discovery, development, 
distribution, and responsible use of medicines; 
3. Create a blueprint for the envisioned Education and         
a toolkit on how to reach it; and 
4. Develop strategies on how to address barriers 
to changing the current state of education and 
to ensure the implementation of the conference 
recommendations.
The FIP Executive Committee appointed a worldwide expert 
group to serve as the planning committee to design the Global 
Conference. The Conference was jointly organised and co-
hosted by FIP and the Chinese Pharmaceutical Association (an 
FIP member organisation in China) and took place on 7 and 8 
November 2016, in Nanjing, China. Over 600 participants from 
46 countries and territories (listed in Annex 1) attended the 
Global Conference. Unique in its format, the global conference 
was a strategic, two-day conference fostering an innovative 
environment at which international experts and leaders 
gathered to adopt a vision to guide the future activities of 
the profession. The first day of the programme consisted of 
high-level presentations on key topics related to education 
in the context of pharmaceutical workforce development, 
around: 1) global policies driving workforce development, 2) 
the imperatives for change in pharmacy and pharmaceutical 
sciences, and 3) the key areas for change in education. Using 
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2.1 A new era for transformative education 
for the future workforce
2.1.1 Pharmacy drivers and changes
The current drivers of transformative change in healthcare 
will clearly require a responsive and paralleled scale up of the 
global health workforce’s capacity. The evolution of health 
professions have largely been a response to changes in 
healthcare systems and population needs. These continuous 
changes drive the reprofessionalisation of the workforce, 
where health professionals are compelled to re-evaluate their 
capacities, both quantitative and qualitative, and reshape 
their roles and practice scopes to be able to meet health 
needs.1 In recent years, the pharmaceutical profession has 
witnessed substantial transformation with unprecedented 
changes occurring within both pharmacy practice and the 
pharmaceutical sciences. 
In pharmacy practice, evolving roles toward more patient-
focused service provision have been a steady trend over recent 
decades.2 Within the redefining concept of pharmaceutical 
care, the practice of pharmacy has undergone a progressive 
shift from being primarily product-oriented to becoming 
increasingly more patient-oriented.3 The profession is under 
pressure to advance and expand the roles of pharmacists and 
pharmaceutical scientists to meet the needs of healthcare 
systems around the world.4-6 Extended and new advanced 
roles for pharmacists, as providers of healthcare services and 
as scientists, are increasingly being recognised and valued 
globally.7 Collaborative practice within healthcare teams 
benefit patient outcomes, and pharmacists worldwide are 
expected to work interprofessionally to provide their essential 
medicines expertise.8,9 Pharmacists are also becoming more 
involved in prescribing medicines and providing critical 
information about the benefits, risks and potential adverse 
interactions to patients and other healthcare providers.10 
The pharmaceutical sciences — the sciences underpinning 
the discovery, development, production and use of medicines 
— are also facing new challenges.11 The ever-pressing need 
to develop safer medicines while ensuring that medicines 
development is efficient and cost-effective means that the 
“science of medicines” will continue to undergo rapid and 
unprecedented transformation.12 The need to discover new 
medcines and develop smart medicines delivery systems is 
shaping the future of the pharmaceutical sciences. These 
changes will affect not only scientists but also pharmacy 
practitioners. For example, the impact of personalised 
medicine on the profession is becoming increasingly 
important.13 Pharmaceutical scientists will need to acquire 
specialist knowledge on genomics and the genetic basis for 
disease and treatment, and pharmacists will need to adapt to 
a resultant shift in the clinical management of patients from 
a one-size-fits-all approach to one that takes into account the 
individual variability of every patient.14,15 
PART 2
TRANSFORMING 
THE PHARMACEUTICAL WORKFORCE
2.1.2 Education for better healthcare
As we enter this new health era, the need for a roadmap to 
drive workforce transformations in the context of the UN’s 
SDGs and the WHO’s Global Strategy is greater than ever. 
Health professional bodies and associations play a central 
role in leading and setting out the vision and blueprints 
for advancing the workforces that they represent. As the 
global professional body representing more than three 
million pharmacists and pharmaceutical scientists around 
the world, FIP endeavours to spearhead the development of 
the pharmaceutical profession and workforce and facilitate 
the implementation of the global health development goals 
within the realm of pharmacy. In doing so, FIP acknowledges 
the importance of understanding our dynamic landscape as 
a prerequisite to setting out a transformation approach. For 
this reason, discussing workforce development drivers was 
a purposively prominent feature of the global conference 
programme.
The discussions focused on the rationale for change by 
considering the evolving nature of future healthcare roles 
and services. They also provided a description of potential 
new scopes of practice, reflecting the desirable profile of 
future pharmacists, pharmaceutical scientists and pharmacy 
students as part of the healthcare and pharmaceutical 
workforce. These discussions revolved around four central 
themes: the centrality of the patient, the changing nature 
of workforce intelligence, roles and services of practice 
and science, and collaboration within healthcare teams. 
These themes, discussed by keynote speakers at the Global 
Conference’s plenary sessionsb, explore concepts and factors 
that drive and shape workforce development plans, strategies 
and frameworks.
b  -   The contents of sections 2.1.3 to 2.1.6 were stimulated by the discussions 
presented by keynote speakers during Session 2: “Global Workforce: 
Education for better healthcare” of the global conference. FIP acknowledges:
Dr John Cahill, global chief executive officer, McCann Health for his 
presentation, briefly summarised for parts of section 2.1.3 “It’s always about 
our patients”; 
Dr Jim Campbell, executive director, Global Health Workforce Alliance, 
and director of the Health Workforce Department, at the World Health 
Organization, for his presentation, briefly summarised for parts of section 
2.1.4 “The changing influence of workforce intelligence”;
Ms Ema Paulino, FIP Professional Secretary, and Prof Giovanni Pauletti, FIP 
Scientific Secretary, for their presentation, briefly summarised for parts of 
section 2.1.5 “Roles and services of practice and science”;
And Mrs Helen Gordon, chief executive, Royal Pharmaceutical Society, UK, for 
her presentation, briefly summarised for parts of section 2.1.6 “Working with 
other health care professionals”. 
All presentations are available at http://www.fip.org/abstracts
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2.1.3 It’s always about our patients
Healthcare professionals undertake their work for the 
ultimate benefit of patients, so it is agreed that the patient 
effectively sits at the centre of the healthcare universe. 
Patients today have ready access to more information than 
ever before. In some cases, they are well informed, empowered 
healthcare consumers who can dictate the quality of health 
services by choosing their advisers and expert counsels, 
selecting their products services and brands, and then sharing 
their experiences. In other cases, more traditional models of 
patient engagement prevail — and, of course, the wide range 
of patient experiences around the world reflects their levels of 
education, the nature and quality of the respective healthcare 
systems and the different means of access available to them. 
Easily accessible search and social platforms enable patients 
to research health, diseases and medicines. Patients’ quests 
for authentic information raise their expectations of health 
services and delivery. Health professionals therefore need to 
strive to remain the patient’s most trusted source. This can be 
achieved not only by ensuring the highest level of workforce 
competency and capability, but also by being able to converge 
and collaborate in a model of shared-care where the patient is 
at the centre. Pharmacists are easily accessible, well informed 
and trusted medicines experts. Pharmaceutical workforce 
education and practice requirements must therefore ensure 
the proper recognition of pharmacists as innovators, problem 
solvers, communicators and consumer health advocates.
2.1.4 The changing influence of workforce 
intelligence
There is a projected gap between the health workforce and 
health system needs around the world, and especially in 
low-income countries. The WHO’s High-Level Commission 
on Health Employment and Economic Growth seeks to 
highlight the benefits across the SDGs from investments 
in the health workforce, reaffirming the objectives set in 
the WHO’s Global Strategy on Human Resources for Health: 
Workforce 2030. Mounting evidence suggests that investing 
in the health workforce employment is not a burden on 
economies,16-18 but rather a multiplier of economic growth.19 
Quality workforce intelligence is key to undertaking robust 
analyses on labour market dynamics to ensure the needed 
capacities are met. The quality of workforce intelligence is 
therefore a priority area in global workforce policies and 
initiatives. The WHO’s National Health Workforce Accounts 
aim to facilitate the standardisation of health workforce 
intelligence and information systems. In line with these global 
directions, FIP has made substantial progress on the workforce 
intelligence front exemplified by the Global Pharmacy 
Workforce Report series20-22 and the recent Global Pharmacy 
Workforce Intelligence Trends Report. 23 These reports provide 
the most comprehensive and up-to-date syntheses of global 
pharmaceutical workforce data.
2.1.5 Roles and services of practice and science
Contemporary roles and services of the pharmaceutical 
workforce span a number of sectors. Community pharmacy, 
hospital pharmacy, pharmaceutical industry, regulations, 
marketing, research, and academia are among the most 
common practice sectors. While the technical expertise and 
professional experiences required differ for each of these 
sectors, the fundamental skills, attitudes and values are 
largely common across all practice areas. Regardless of the 
practice sector, a qualified global workforce of pharmacists 
and pharmaceutical scientists is anticipated to share several 
characteristics in the future that include: diverse educational 
backgrounds, high-level inter-/cross-disciplinary training, 
collaborative approach to healthcare team work, commitment 
to undertake life-long learning, cultural tolerance, optimism 
and self-motivation, personalised professional development 
plans, and ability to receive assistance from internal and 
external support structures. In addition to this common 
paradigm, bridging the gaps between science and practice 
in education is another factor driving the global vision for 
workforce development. Integrated healthcare provision 
and medicines expertise requires a more “one workforce” 
approach, and the creation, education and training of a flexible 
and adaptable workforce requires us to reduce sectoral 
boundaries in workforce planning.
2.1.6 Working with other healthcare professionals
Delivering optimal patient care requires multi-professional 
collaboration between all healthcare team members. A well 
developed global consensus reinforces that collaboration in 
healthcare provision leads to better outcomes for patients. 
This is especially important as healthcare systems become 
more complex, needing effective and creative solutions 
generated collectively by all healthcare professionals. 
Interprofessional education is the foundation for collaborative 
practice and FIP’s “Interprofessional education in a 
pharmacy context: Global report” from 2015 describes the 
key tenets of interprofessional education, relationships 
with collaborative practice, and the emerging links to better 
patient care.9 Implementing interprofessional collaboration 
is not without challenges, and the role of professional 
associations and bodies is integral to making collaborative 
work a reality. Leadership organisations need to gear efforts 
towards providing the rationale for collaborative practice, 
and to promote and lead change locally and globally. By 
actively contributing to and progressing projects by other 
organisations, such as FIP, pharmacy leadership bodies can 
support the development of a pharmaceutical workforce that 
is ready and able to work with other healthcare professionals.
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2.2 Adoption of a roadmap for 
a needs-based pharmaceutical 
workforce transformation
Transforming the global workforce requires a global vision 
with clear and consensus-based objectives. FIP led the 
adoption of a developmental roadmap for continuous 
education and training through a shared vision for 
improving global health. Through the global conference, 
FIP set a roadmap that can facilitate the transformation of 
pharmaceutical education and workforce by providing the 
appropriate strategic tools to support and develop quality 
driven education at national levels. An extensive consultation 
process (before and at the Global Conference) resulted in three 
major documents that were presented and adopted at the 
Global Conference on Pharmacy and Pharmaceutical Sciences 
Education:
1. Global Vision for Education and the Workforce
2. Pharmaceutical Workforce Development Goals
3. Nanjing Statements on Pharmacy and Pharmaceutical 
Sciences Education
The methodologies underlying the development of these 
three documents are summarised in Table 2.1. The planning 
and drafting of the documents, as well as the extensive 
internal and external consultation processes are detailed. 
Draft versions of the Nanjing Statements were available for 
public consultation between April and September 2016, and 
the Global Vision and Pharmaceutical Workforce Development 
Goals (PWDGs) were available for public consultation 
between July and September 2016, to engage individuals and 
professional bodies around the world. Every pharmacist, 
pharmaceutical scientist, pharmacy student, pharmaceutical 
association corporate partners, and other stakeholders in 
health were welcome to contribute in order to shape the 
future of pharmacy and pharmaceutical sciences education 
and training.
Draft of the Global Vision was 
developed by FIP experts
Global Vision for 
Education and 
the Workforce
Pharmaceutical 
Workforce 
Development 
Goals (PWDGs)
Nanjing 
Statements on 
Pharmacy and 
Pharmaceutical 
Sciences 
Education
Draft of the PWDGs was the 
result of the content analysis 
of FIPEd output since 2008
Draft of the Statements 
on Pharmacy and 
Pharmaceutical Sciences 
Education prepared by the 
Working Group on Statements 
from the Planning Committee
Member 
Organisations, 
Executive 
Committee, Bureau, 
Boards and FIPEd
Member 
Organisations, 
Executive 
Committee, Bureau, 
Boards and FIPEd
Member 
Organisations, 
Executive 
Committee, Bureau, 
Boards and FIPEd
99 comments, suggestions and support 
were received from 31 countries and 
territories
689 comments, suggestions and support 
were received from 23 countries and 
territories
3,216 comments, suggestions and 
support were received from 22 
countries and territories
Live voting process by country 
delegates during the global conference
Online iteration after global conference 
to understand country delegates’ voting 
decisions
Planning and Drafting FIP Consultation Public and organisational consultation
Table 2.1: Planning and drafting, and consultation processes behind final 
drafts of the Global Vision, PWDGs, and Nanjing Statements.
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that deploys its knowledge, skills and abilities to the fullest 
degree in a wide array of environments and in collaboration 
with other stakeholders in healthcare. 
FIP believes it is important that we articulate our vision for 
education, training and workforce development and for the 
progressive transformation of the overall workforce. This 
vision links to current global health and health education 
policy for all our member organisations and partners and the 
anticipated health challenges of the future.
Supporting and developing high standards
of education and training 
Through this vision for education and workforce, FIP seeks 
to promote and enhance the health and well-being of civil 
society through professional leadership and development 
of our professional workforce. FIP will also seek to ensure 
our profession’s contribution to the health and well-being of 
patients and the advancement of pharmaceutical sciences. 
In the delivery of these broad aims FIP believes that 
professional education, training and development should 
be primarily directed to:: 
Producing high quality professionals for high quality 
patient care, public health and scientific advancement 
objectives, ensuring all education and training delivered 
to our professional workforce is of the highest quality and 
prepares them well for current and future roles.
FIP believes it is our responsibility to engage the whole 
pharmaceutical workforce with this vision, to lead on, and 
define the skills, knowledge, attitudes and behaviours of 
pharmacists, pharmaceutical scientists, pharmacy technicians 
and other pharmacy support workforce cadres in all settings.
Developing our vision for the whole pharmaceutical 
workforce 
FIP believes that a needs-based, outcomes-focused approach 
to education, workforce development and continuing 
education and training should be adopted. This means 
promoting models of education and training that ensure 
that all members of our workforce have access to the highest 
quality education and training experiences possible. 
Pharmacy is a science-based profession and also a patient-
facing profession; it is essential to build in learners, from initial 
education and training onwards, the capacity to demonstrate 
empathy for others, strong interpersonal communication skills 
and the understanding of the importance of teamwork and 
collaboration. The challenges of development, distribution, 
and responsible and safe use of medicines require a diverse 
workforce that is prepared to provide leadership for change 
in practice and to commit to lifelong learning to keep pace 
and lead the process with continuous changes in science and 
patient care. 
2.2.1 Global Vision for Education 
and Workforce
FIP developed a Global Vision for Education and Workforce 
underpinned by global strategies and recommendations 
on human resources for health and translated into a 
pharmaceutical expertise context. This document aims to 
provide a vision for the transformation of pharmaceutical 
education in the context of current and future workforce needs. 
Developed in the context of education and training for the 
global pharmaceutical workforce, the global vision describes 
FIP’s role in leading change on a global level and links to 
current global health and health education policies. It consists 
of a description of the future directions for the profession 
and how education can support evolution in that direction. 
Pharmaceutical leaders and stakeholders will be able to rely 
on it for the development of their own strategies (based on 
local needs), and for advocacy perspective towards policy-
makers and all stakeholders. 
The global vision begins with the Nanjing Declaration, which 
signifies the joint professional commitment of all pharmacists, 
pharmaceutical scientists, professional leadership 
organisations and government agencies to drive and support 
the development of the pharmaceutical workforce in line with 
this vision. 
NANJING DECLARATION
Pharmacists and pharmaceutical scientists accept 
responsibility for the development and sustainability of 
an adaptable and capable global workforce working in 
partnership for better healthcare through transformative 
and continuous education. Our professional workforce 
will continuously strive to develop new medicines and to 
improve the use of existing medicines for better healthcare. 
Professional leadership organisations and government 
agencies can contribute to this vision by supporting 
progressive policies for professional development and 
practitioner recognition processes.
Leading change
The FIP Centennial Declaration in 2012 on improving global 
health by closing gaps in the development, distribution 
and responsible use of medicines stated: “Pharmacists 
and pharmaceutical scientists accept responsibility and 
accountability for improving global health and patient health 
outcomes by closing gaps in the development, distribution 
and responsible use of medicines.” 
In support of this centennial declaration is the 
acknowledgement that worldwide variability exists in how 
pharmaceutical scientists, pharmacists and pharmacy support 
staff are educated, trained and utilised. The challenges of 
development, distribution and responsible use of medicines 
can only be met with an adaptable pharmaceutical workforce 
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A needs-based approach to workforce 
and patient care 
Our vision for the advancement and development of our 
workforce is aligned with identified drivers of demographic 
changes in healthcare, continuous developments in 
therapeutic technologies and the need for better access to 
medicines and medicines expertise. This means a continuous 
process of evolution and development.
An evolving pharmaceutical workforce is one that can adapt 
its core roles and responsibilities to meet the new and 
emerging needs of patients and civil society. For FIP, this 
means providing the necessary global leadership to encourage 
the development of the pharmaceutical workforce across all 
sectors to meet changing demographic and healthcare needs. 
FIP needs to promote advanced generalist and specialist skills 
development, leadership development and, most importantly, 
the flexibility to adapt to changing patient and health system 
needs.
The global workforce must be adaptable, flexible and 
constantly developed. It will need to be scientifically literate, 
holistic and patient-focused. Our education and training 
approach to getting the best from our workforce requires a 
focus on patient-centred professionalism, better healthcare 
partnerships both globally and regionally, and good clinical 
and scientific leadership.
Pharmacy leaders from practice, education and research 
should engage in workforce planning efforts in each country 
and region to ensure that plans include due attention to 
the integration of pharmacists, pharmaceutical scientists 
and pharmacy support cadres to meet local health needs. 
Workforce planning efforts should also be documented and 
shared internationally.
To pursue these aims, FIP believes that the development of a 
high level set of clear and common learning standards that are 
manageable in number will directly promote better education 
and healthcare outcomes..
Our commitment: The FIP vision for the 
pharmaceutical workforce
1. All patients will have access to the best pharmaceutical 
healthcare through a high quality pharmaceutical 
workforce. There is no healthcare without a properly 
qualified workforce. 
2. All our pharmacy professionals responsible for providing 
patient care will ensure the adoption of actions for the 
responsible use of medicines that are clinically effective, 
safe and of suitable quality. 
3. Our workforce will acknowledge and recognise our 
own core responsibilities for education, training and 
development of clinical, scientific and academic roles, 
and of pharmaceutical healthcare leadership. 
With these principles in mind, models of education and 
training need to be flexible and adaptable to allow for 
innovations and developments led by educational experts, 
practitioners and leaders, among others, within responsible 
organisations.
Global education, training and development 
principles and imperatives 
FIP believes that our strategic approach to education and 
workforce development should be grounded in the following 
principles:
1. The future workforce needs to be flexible in its 
development, adaptable to change and consciously 
competent within known scopes of practice. 
2. Education provider organisations and education 
stakeholders should transparently support quality-
driven development of education programmes founded 
on scientific knowledge and expertise in medicines. 
3. Education and training in practice and science-oriented 
environments should reflect the best evidence and 
experience for an excellent education, including 
workplace education models and work-based learning 
systems. 
4. Education providers should ensure that all teachers and 
tutors have access to teacher training programmes and 
development in order to become high quality teachers 
and trainers for our profession — we cannot achieve the 
best workforce without the best educators. 
5. All members of the pharmaceutical workforce should 
have access to the best-practice education, the best in 
clinical, scientific and expert leadership and the best 
learning experiences to help equip them to become 
competent and capable practitioners in all relevant 
fields. 
6. Access to systems for continuing professional 
development are essential for maintaining and 
advancing the competencies and capabilities of 
pharmacists and pharmaceutical scientists throughout 
their careers. 
7. Workforce planning for healthcare for individuals 
and populations should be based on team-based 
collaborative care models and interprofessional models 
involving all relevant healthcare professionals.
Sufficient financial support from public and private sources 
must be available to sustain the mission of educational 
institutions that prepare the pharmaceutical workforce. 
There should be support to promote the participation of 
academic faculties, professional organisations, scientific 
societies, practitioners, preceptors and students in national 
and international activities of pharmacy and healthcare.
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2.2.2 The Pharmaceutical Workforce Development 
Goals
Driven by the development of the Global Vision, the 
Pharmaceutical Workforce Development Goals (PWDGs) were 
developed as a means to activate and give purpose to the 
Vision. They were adopted by the profession to implement the 
Vision. These global Goals describe workforce development 
through education and will be applicable to the primary 
mission of professional leadership organisations. There are 13 
PWDGs that have been grouped into three clusters: 
1. Academy (focus on the schools, universities and 
education providers); 
2. Professional development (focus on the pharmaceutical 
workforce); and 
3. Systems (focus on policy development, governmental 
strategy and planning, and monitoring systems). 
The 13 goals are aimed at supporting the implementation 
of the Global Vision for Education and Workforce. They are 
aligned with major international policies (from the UN SDGs 
and the WHO Human Resources for Health Strategy 2030). The 
PWDGs will be a significant directive force for actions, fund-
raising and near- and long-term deliverables for FIP. 
FIP will adhere to a set of principlesc for PWDGs that will guide 
the subsequent plan of action. These will form the basis of 
yearly action planning for FIP, FIPEd and relevant stakeholders. 
Pharmaceutical leaders and stakeholders will be able to use 
them to assess the current stage of their own workforce 
development and capacity, assisting the development of 
strategies at national level, as well as fostering engagement 
and dialogue with policy-makers.
here has been no attempt to prioritise or attach levels of 
importance to individual PWDGs; the current imperative is to 
disseminate their overall scope and range, and to highlight to 
national leadership organisations their potential influence 
and adaptability from a national perspective. For each PWDG, 
a summative set of drivers, imperatives and indicators is 
provided. Table 2.2 lists the 13 PWDGs. These 13 goals were 
the product of extensive external and internal consultation 
processes summarised earlier in Table 2.1. 
4. All members of our workforce should have equitable 
access to education and development opportunities 
throughout their careers with a particular emphasis     
on early career foundation training and development. 
5. FIP will commit to supporting the scientific workforce 
to constantly provide better medicines and healthcare 
through the application of research and development 
science. 
6. All pharmacy professionals will be able to demonstrate 
continuous development in their skills, knowledge 
and competencies using appropriate standards and 
evidence-led professional development frameworks 
in all care, science and academic settings and for the 
ultimate benefits of patients and civil society. 
7. Our pharmaceutical workforce will be valued across all 
countries and territories and at all career stages and 
recognised by patients and civil society for its impact 
and expert contribution to healthcare.
The FIP commitment to supporting this vision
Patients, civil society, health system planners, governments 
and the healthcare professionals we work with have a clear 
interest in the impact of the pharmaceutical healthcare 
workforce. FIP will therefore identify global priorities for 
professional development, education and training required 
to achieve this vision.
FIP will work with and influence policymakers on the 
transformation of education and training for our workforce 
to improve care and outcomes for patients, including the 
advancement of medicines science.
FIP will promote recognition of the importance of quality 
assured lifelong learning provision for our global workforce.
FIP will promote access to expertise in workforce development 
and support tools, including the development of workforce 
intelligence systems and workforce planning models.
A robust global pharmacy and pharmaceutical sciences 
workforce, supported by transformative education practices, 
will be able to lead the changes required to assure universal 
access to quality medicines and medicines information. 
Further, the pharmaceutical workforce can contribute 
significantly to the appropriate use of medicines through 
research and by active participation in pharmaceutical 
care in collaboration with patients and other healthcare 
professionals.
To that end FIP commits to the Global Vision for Education 
and Workforce. 
c  -   PWDG principles and goals are aligned with the Nanjing conference 
objectives as described in the terms of reference.
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Table 2.2: The Pharmaceutical Workforce Development Goals: 
Description, rationale, drivers and potential indicators.
1. Academic 
capacity
2. Foundation 
training and 
early career 
development
Academy
Focus on 
the schools, 
universities and 
education 
providers
Engagement with 
pharmaceutical 
higher education 
development 
policies and ready 
access to leaders in 
pharmaceutical science 
and clinical practice 
in order to support 
supply-side workforce 
development agendas.
Foundation training 
infrastructures in 
place for the early 
post-registration 
(post-licensing) years 
of the pharmaceutical 
workforce as a basis 
for consolidating initial 
education and training 
and progressing the 
novice workforce 
towards advanced 
practice.
• Increase the capacity to provide a competent 
pharmaceutical workforce by developing initial 
education and training programmes that are 
fit for purpose, according to national health 
resource needs (clinical practice, pharmaceutical 
science areas and stakeholders across all cadres). 
• Develop new and innovative ways to 
attract young pharmacists into all areas of 
pharmaceutical practice and science (e.g. 
encourage young pharmacists to consider 
careers in clinical academia, as preceptors/
trainers, in industrial pharmacy, regulatory 
sciences, nuclear and veterinary pharmacy, 
among others).
• Capacity building should include the ability to 
meet minimum national standards of facilities, 
educators and student support in order to ensure 
access to quality education for all students.
• Enhance interprofessional education and 
collaboration with key stakeholders, including 
governments, national and international 
pharmacy/pharmaceutical organisations and 
patient advocacy groups to achieve sustainable 
solutions for capacity development. 
• The clinical academic educator workforce needs 
more attention to training, career development 
and capacity building, which must, importantly, 
include research capacity enhancement.
• Create clear and purposeful education and 
training pathways/programmes to support 
post-registration (post-graduation) foundation 
training (clinical practice and pharmaceutical 
science areas).
• Develop early career maps and frameworks to 
support a seamless transition into early career 
practice and towards advanced practice.
• Develop structured approaches to early 
career mentoring systems to support 
novice practitioners to engage with peers 
and preceptors (in clinical practice and 
pharmaceutical science areas across the 
pharmaceutical workforce).
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
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3. Quality 
assurance
4. Advanced 
and specialist 
expert 
development
Academy
Focus on 
the schools, 
universities and 
education 
providers
Professional 
development
Focus on the 
pharmaceutical
workforce
Transparent, 
contemporary and 
innovative processes for 
the quality assurance of 
needs-based education 
and training systems.
Education and training 
infrastructures in place 
for the recognised 
advancement of 
the pharmaceutical 
workforce as a basis 
for enhancing patient 
care and health system 
deliverables.
• Ensure the quality of the workforce by quality 
assuring the continuous development and the 
delivery of adequate and appropriate education 
and training; quality assurance needs to address 
academic and institutional infrastructure 
in order to deliver the required needs and 
competency-based education and training. 
• Establish standards-based global guidance 
for quality assurance of pharmacy and 
pharmaceutical science education in the context 
of local needs and practice.
• Implement fair, effective and transparent 
policies and procedures for quality assurance of 
pharmacy and pharmaceutical science education 
and training. 
• Define critical stakeholder input on development 
of adequate education and training and fair and 
effective policies, including necessary student 
input.
• Need for a common and shared understanding of 
what is meant by “specialisation” and “advanced 
practice” in the context of scope of practice and 
the responsible use of medicines.
• Ensure competency and capability of an 
advanced and expert pharmacist in all sectors 
(including specialisations extending into 
industry and administration settings) for greater 
optimisation of complex pharmaceutical patient 
care. This may now include prescribing roles 
within a recognised scope of practice.
• Systematic use of professional recognition 
programmes/systems as markers for 
advancement and specialisation across the 
workforce, including advanced pharmaceutical 
scientists.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
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6. Leadership 
development
7. Service 
provision and 
workforce 
education and 
training
Professional 
development
Focus on the 
pharmaceutical
workforce
Strategies and 
programmes in place 
that develop professional 
leadership skills 
(including clinical and 
executive leadership) 
for all stages of career 
development, including 
pharmaceutical sciences 
and initial education 
and training.
A patient-centred and 
integrated health 
services foundation 
for workforce 
development, relevant 
to social determinants 
of health and needs-
based approaches 
to workforce 
development.
• Creation of programmes/strategies for the 
development of leadership skills (including tools 
and mentoring systems), to support pharmacists 
and pharmaceutical scientists through their 
careers.
• Advocacy for leadership development in 
healthcare teams, linked to collaborative 
working activities (for example, promotion of 
team-based approaches to healthcare service 
delivery). 
• Ideally, this should be linked with competency 
and foundation and early year career 
development activities.
• Systematic development of education and 
training activities based on local healthcare 
systems, their capacity and funding.
• Evidence of systematic development policies 
and strategies for the strengthening and 
transforming pharmaceutical workforce 
education and the systematic training of 
trainers/educators.
• Education providers must ensure, by the 
provision of evidence-based approaches, that 
lecturers/teachers/trainers are themselves 
appropriately trained for capability and 
competency.
• Enable the pharmaceutical workforce* and key 
stakeholders to promote health equity through 
actions related to social determinants of health.
5. Competency 
development
Clear and accessible 
developmental 
frameworks describing 
competencies and 
scope of practice for all 
stages of professional 
careers. This should 
include leadership 
development 
frameworks for the 
pharmaceutical 
workforce.
• Use of evidence-based developmental 
frameworks to support the translation of 
pharmaceutical science within scope of practice, 
across all settings and according to local/
national needs.
• Support professional career development by 
using tools, such as competency frameworks, 
describing competencies and behaviours across 
all settings.
• Evidence of clear policy that links leadership 
development (from early years) with competence 
attainment for the advancement of practice 
activities.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
19Transforming pharmacy and pharmaceutical sciences education
9. Continuing 
professional 
development 
strategies
10. 
Pharmaceutical 
workforce 
gender and 
diversity 
balances
Professional 
development
Focus on the 
pharmaceutical
workforce
Systems
Focus on policy 
development, 
governmental 
strategy and 
planning, and 
monitoring 
systems
All professional 
development activity 
clearly linked with 
needs-based health 
policy initiatives and 
pharmaceutical career 
development pathways.
Clear strategies for 
addressing gender and 
diversity inequalities 
in pharmaceutical 
workforce 
development, 
continued education 
and training, and 
career progression 
opportunities. 
• Demonstration of strategies to address the 
gender and diversity inequalities across 
all pharmaceutical workforce and career 
development opportunities. 
• Ensure full and effective participation and 
equal opportunities for leadership at all 
levels of decision-making in pharmaceutical 
environments; avoidable barriers to participation 
for all social categories are identified and 
addressed.
• Engagement and adoption of workforce 
development policies and enforceable 
legislation for the promotion of gender and 
diversity equality; policies and cultures for the 
empowerment of all without bias.
• This should be applicable to academic capacity 
and leadership development activities.
• Evidence of an effective continuing professional 
development strategy according to national and 
local needs.
• Development of programmes to support 
professional development across all settings of 
practice and all stages of a pharmacist’s career.
• Ideally, this should be linked with all professional 
development activities across the workforce.
• Education in continuing professional 
development strategies and self-directed 
behaviours should be initiated at the student 
level.
8. Working 
with others     
in the 
healthcare 
team
Clearly identifiable 
elements of 
collaborative working 
and interprofessional 
education and training 
which should be a 
feature of all workforce 
development 
programmes and 
policies.
• Evidence of policy formation to demonstrate 
how healthcare professionals can develop and 
engage in partnerships to achieve better health 
outcomes.  
• Develop education and training strategies/
programmes to ensure collaboration within the 
pharmaceutical workforce and training   
on medicines for other healthcare professionals.
• Ideally, this should be linked with formal 
professional development activities.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
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12. Workforce 
intelligence
13. Workforce 
policy formation
Systems
Focus on policy 
development, 
governmental 
strategy and 
planning, and 
monitoring 
systems
A national strategy and 
corresponding actions 
to collate and share 
workforce data and 
workforce planning 
activities (skill mixes, 
advanced and specialist 
practice, capacity). 
Without workforce 
intelligence data there 
can be no strategic 
workforce development.
Clear and manageable 
strategies to 
implement 
comprehensive needs-
based development 
of the pharmaceutical 
workforce from initial 
education and training 
through to advanced 
practice.  
• FIP should aim to have a global workforce 
compendium of case studies developed by 2019.
• Develop monitoring systems to identify 
workforce trends to enable decision making 
on deployment and supply of pharmaceutical 
workforce noting that time-lags are often 
present in these activities. 
• Ideally, this should be linked with stewardship 
and leadership for professional leadership 
bodies.
• Adopt and strengthen sound policies and 
enforceable legislation for holistic needs-based 
approaches to professional development across 
all settings and stages.
• Develop strategies where pharmaceutical 
science and professional services are the driving 
forces for this activity.
PWDGCluster PWDG general 
description.
Countries/territories 
and member 
organisations should 
have:
Rationale, drivers, and potential indicators
11. Workforce 
impact 
and effect 
on health 
improvement
Evidence of the impact 
of the pharmaceutical 
workforce within 
health systems and 
health improvement. 
• Engagement with systems to measure the 
impact of the pharmaceutical workforce on 
health improvement and healthcare outcomes. 
Links with needs-based education, training and 
workforce planning.
• Gather continuous data points to monitor the 
performance of the pharmaceutical workforce.
• Ideally, this should be linked with strategies to 
enhance workforce intelligence.
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The workshops aimed to address the drivers and challenges 
of achieving the PWDGs on a global scale. This includes key 
messages on what the challenges are to achieving the goals, 
and what strategies and tactics can be used to overcome 
these. The realistic ways of promoting and disseminating the 
goals and engaging with stakeholders were also discussed. 
Table 2.3 presents a summary of the key workshop outcomes 
for each area of focus and related PWDGs.
Table 2.3 Global conference workshop descriptions and summaries 
of key outcomes.
The evidence-based PWDGs were designed to be achievable, 
measurable, feasible, tangible, developmental and relevant to 
all countries and territories. To prepare the implementation 
of the goals at the national level, a series of workshops was 
organised to identify and share best practices to promote 
educational change. The PWDGs provided context for the 
workshops’ seven areas of focus:
1. Initial and early education
2. Quality assurance and accredition
3. Educating for collaborative working 
4. Practice and science
5. Educating for future goals
6. Educating for advanced practice
7. Clinical practice
This workshop provided 
an overview on how to align 
initial education with the 
country needs. It also focused 
on the first 1,000 days of 
practice, addressing suitable 
training and mentorship 
for young pharmacists and 
pharmacy students.
This workshop provided a 
conceptual framework for the 
design, implementation and 
assessment of the quality of 
contemporary educational 
programmes.
Workshop area of 
focus and related 
PWDG(s)
Workshop 1:
Initial and early 
education
PWDG(s): 
1. Academic 
capacity
Workshop 2:
Quality assurance 
and accreditation
PWDG(s): 
3. Quality 
assurance
The definition scope of PWDG 1 Academic Capacity is wide and 
can include a number of concepts such as: having the right mix 
of academic expertise; quantity, quality, infrastructure; optimised 
learning environment; and producing pharmacists who can 
meet the country needs and adapt to future ones. A number of 
drivers of implementing the first PWDG were identified, and these 
include: automation (e.g., e-learning and simulation); applying 
best practices; and creating collaborative education and training 
environments. In addition, targets for implementation can be 
found in: developing graduate employability skills; reviewing 
evaluation methods; and adopting an outcomes-based learning 
system.
The challenges in achieving PWDG 3 can lie in: diversity within 
and between countries; resources (e.g., human resources and 
funding); stakeholder engagement; resistance to change; 
governmental control and regulatory constraints. Identifying 
solutions and addressing these challenges can be accomplished 
through: communicating and collaborating with stakeholders; 
developing strategies to incentivise stakeholders and 
government bodies; encouraging more association-driven 
strategies; seeking FIP assistance and support; and using tools 
already developed. Identifying gaps, conducting needs analyses, 
setting implementation targets, and capitalising on existing 
capacities and resources can all facilitate achievement 
of the goal.
Workshop description Summary of key outcomes
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This workshop addressed 
interprofessional and 
intraprofessional education, 
and models of collaboration 
between higher education 
institutions, sectors, science 
and practice.
This workshop addressed how 
education prepares science 
to translate into practice and 
practice to inform science.
This workshop addressed 
future roles for pharmacists 
and pharmaceutical 
scientists, including 
the scope, technological, 
clinical and scientific aspects 
of new roles.
Workshop area of 
focus and related 
PWDG(s)
Workshop 3:
Educating for 
collaborative 
working
PWDG(s): 
6. Leadership 
development
8. Working 
with others
Workshop 4:
Practice and 
science
PWDG(s): 
7. Service 
provision and 
workforce 
education and 
training
13. Workforce 
policy formation
Workshop 5:
Educating for 
future goals
PWDG(s): 
6. Leadership 
development 
9. Continuing 
Professional 
Development 
strategies
Achieving leadership, PWDG 6, depends on students being 
provided with early leadership development opportunities and 
having leadership as part of accreditation standards. Applying 
leadership skills is imperative in developing relationships with 
other professionals to enhance collaboration. Achieving PWDG 8 
depends on nurturing collaborative skills in pharmacy students 
from the first semester onward, as well as developing more 
collaborative experiential training programmes. Transparency, 
trust and confidence are integral to successful collaborative 
practice. Collaborative practice drivers such as engagement 
from professional associations, credentialing incentives and 
remuneration models can facilitate achieving PWDG 8. Examples 
of ways to disseminating the implementation of include 
establishing guidelines, scientific publications and centres 
of excellence.
Participants discussed goals terminology, demonstrating 
the importance of reaching consensus on definitions. They 
also shared ways of integrating science and practice through 
education. One was through redesigning initial education such 
that pharmacy students are introduced to practice from day 1. 
In addition to undergraduate education, targeting postgraduate 
studies can be a means to science/practice integration 
(e.g., clinical practice-based research and data collection). 
Recalibrating the curriculum to accommodate new emerging 
therapies and advanced services was also identified. And 
introducing innovative modules that allow students to design 
new pharmaceutical services would encourage them to think 
about the link between science and practice.
It is important to understand the motivating factors that 
influence pharmacists’ CPD habits in order to address the 
challenges facing goal achievability. It is also important for FIP to 
communicate strategies to member organisations to help them 
engage with stakeholders, such as the government, in order to 
facilitate meeting the PWDGs. Updated documents and guidance 
documents are a critical first step towards achieving the goals.
Outcomes regarding PWDG 6 on leadership development 
resonate with other workshop outcomes for same goal. 
Empowering students with leadership-fostering activities has 
been identified as a key driver. Targeting mentoring programmes 
and creating centres of excellence can benefit both PWDGs 6 
and 9. Disseminating the implementation of PWDG 6 depends 
on developing specific processes describing how pharmacists 
can be engaged to take up leadership programmes.
Workshop description Summary of key outcomes
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This workshop addressed 
specialisation, professional 
development, professional 
recognition and credentialing.
This workshop addressed how 
to transform education of 
pharmacists to better prepare 
them for clinical roles. 
Workshop area of 
focus and related 
PWDG(s)
Workshop 6:
Educating 
for advanced 
practice
PWDG(s): 
2. Foundation 
training 
4. Advanced 
and specialist 
development
Workshop 7:
Clinical practice
PWDG(s): 
5. Competency 
development
11. Workforce 
impact
There are major variances amongst different countries, in 
terms of terminology recognition, legislation and scope of 
practice, infrastructures of practice sites, and existing support 
structure (e.g., professional organisations). Sharing experiences 
(both positive and negative) and best practices is important 
to achieving the goals. There is a need for top-down policy 
and educational structural changes to progress advanced and 
specialist development and practice. Expanding the role of FIPEd 
beyond congresses and reports to disseminating ”how to” guides 
that can assist with real policy implementation is important. 
Also, developing a global advanced practice and specialisation 
framework (in addition to the FIP competency framework that 
already exists) can help countries advance practice in their 
jurisdictions.
There is consensus that clinical practice refers to patient-focused 
care in any practice setting and that expanding the role of 
pharmacists in clinical practice is both desirable and achievable. 
There are a number of drivers to embracing clinical roles: refining 
practice scope and activities to have time for clinical practice; 
fostering new ways of working that connect pharmacists to other 
members of the healthcare team; establishing remuneration 
systems for the outcomes of clinical services; and assuring 
competence to deliver excellent patient care. Additionally, there 
are regional differences regarding progress toward clinical 
services, and countries developing new services may benefit from 
learning lessons from others who have already implemented 
clinical practices.
Workshop description Summary of key outcomes
The interactive sessions were intended as a tool in identifying 
best practices for promoting change and their outcomes 
are critical for future success. The workshop delegates and 
participants represented many countries, organisations 
and scopes of expertise. Participant feedback and workshop 
outcomes will be used to feed directly into the global 
transformation agenda. 
Common themes were identified across the achievability of 
the goals, assessment and metrics, financial incentives and 
the role of FIP. The achievability of the PWDGs depends on 
several factors, including consideration of locality needs 
and capacities when adopting the goals. Engagement with 
stakeholders and engagement from and between professional 
associations are additional important factors to achieving 
workforce goals.
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context leading to their decision at the global conference. 
Based on the post-Nanjing online consultation and the 
collective agreement of the country delegates, the working 
group kept one, consolidated four into two and eliminated one 
of the statements. 
The final version consists of 67 statements adopted by 
consensus, representing the international expectations on 
what an effective pharmaceutical education system looks like 
to meet local needs. They are grouped into eight clusters:
1. Shared Global Vision 
2. Professional Skills Mix
3. Recruitment of Students
4. Foundation Training and Leadership
5. Experiential Education
6. Resources and Academic Staff
7. Quality Assurance
8. and Continuing Professional Development
2.2.3 Statements on Pharmacy and Pharmaceutical 
Sciences Education (Nanjing Statements)
The Nanjing Statements on Pharmacy and Pharmaceutical 
Sciences Education describe the envisioned future for 
pharmaceutical education needed to enhance professional 
standards worldwide. The Nanjing Statements are intended 
for education providers, including Schools of Pharmacy 
and providers of Continuing Professional Development and 
Continuing Education. They are to be used for the purposes 
of self-assessment and monitoring (at country level or at the 
education provider level), identification of gaps and strategic 
planning, and improving the process of education. 
The Nanjing Statements underwent extensive consultation 
and validation processes before, during and after the global 
conference.
Initial development of the Nanjing Statements
The Nanjing Statements were developed by FIP to guide 
the process of educational reform. The Global Conference 
Planning Committee set up a working group dedicated to 
the development of the original draft Nanjing Statements. 
This draft list of statements underwent extensive review 
by the entire Planning Committee, FIP Bureau, FIPEd, FIP 
Boards, and expert groups to ensure completeness and a 
balanced representation of science and practice. A total of 80 
statements grouped into eight clusters comprised the first 
draft.
Validation Phase I
The 80 statements were subject to public consultation 
before the Nanjing Conference. A total of 3,216 comments, 
suggestions and supporting remarks were received from 
22 countries and territories. Comments offered included 
clarifications, suggestions for consolidation and wording 
changes. These comments were carefully considered by the 
working group during their revision of the draft, resulting in a 
set of 70 Statements. 
Validation Phase II
The 70 statements underwent a second validation phase at 
the global conference in Nanjing. A live voting process by 
36 delegations from 37 countries was arranged to evaluate 
the level of global consensus and drive a consensus-based 
validation approach by stakeholders from around the world. 
From the 70 statements voted upon, 64 reached more than 
80% of agreement at the global conference. Six statements 
received less than 80% of votes in agreement but all were 
above 50%.  
Validation Phase III
The working group conducted an online iteration within 
country delegates on the six statements which did not reach 
the 80% approval rate, to understand the reasoning and 
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Nanjing Statements on Pharmacy 
and Pharmaceutical Sciences Education
Cluster 1: Shared Global Vision
Description
on the 
cluster:
1.1
1.2
1.3
1.4
1.5
A shared global vision promotes workforce development in the context of pharmaceutical education 
and training. This global vision should help professional leadership bodies, educators and regulators 
in developing a national or regional vision based on the priorities and resources of the country or region, 
with the aim of developing new medicines and improving their use for better health.
Workforce planning, at national and local levels, should include the roles of all relevant personnel, 
(e.g., pharmacy technicians/assistants, generalist pharmacists, specialists, advanced practitioners 
and pharmaceutical scientists) sufficient to meet local health needs as part of the healthcare system.
The education and training of pharmacists should have an underlying foundation in both the physical 
and biological sciences sufficient to prepare the student for current and future practice.
Schoolsd should teach students so they can attain competencies in professional values, ethics and 
professionalism by graduation in order to improve the responsible use of medicines, their discovery, 
development, manufacturing and distribution.
Schools should ensure that the needs and future trends in healthcare delivery, advancement in the 
profession, the pharmaceutical industry and education are taken into account to develop and update 
the curriculum.
Schools should promote the message that pharmacists are patient advocates and care providers who 
provide / facilitate efficient access to quality medicines with the goal of helping patients make the best 
use of their medicines.
d  -   In this document, schools are defined as “Schools of Pharmacy and/or 
Pharmaceutical Sciences”
1.6 Academic staff should add to the evidence that pharmacists can improve the responsible use of medicines 
to improve effectiveness, safety and efficient use of limited resources and should convey to the students 
the skills to achieve this.
1.7
1.8
All pharmacists and academic staff should be encouraged to participate in scholarly activity to generate 
new knowledge in their area of expertise.
Pharmacists should be champions for good health and wellness promotion, preventive medicine and 
holistic patient management. Pharmacists must undertake this through an economic, social, cultural 
and ethical perspective.
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Cluster 2: Professional Skills Mix
Description
on the 
cluster:
2.1
2.2
2.3
2.4
2.5
Pharmacists in all settings and pharmaceutical scientists need competence, skills, knowledge 
and attitudes to meet the needs of the public and interact with other healthcare professionals. 
The proper balance of science and practice should be established and taught: biomedical sciences, 
including pathophysiology, pharmacology and pharmacotherapy, should be distributed throughout 
the curriculum and should be taught in the context of patients and medicines.
Aspects of pharmaceutical chemistry, pharmaceutical technology and pharmaceutical analysis should 
be included in the curriculum to present the processes related to the development, production and 
registration of medicinal products. Students should be taught both basic pharmaceutical sciences and 
the use of medicines in the context of the patient care.
Pharmaceutical regulatory sciences should be included as part of the curriculum to provide 
knowledge and skills to students relevant to ensure the quality and safety of medicines and 
appropriate professional practice.
Besides the basic sciences, clinical, social and administrative sciences are fundamental when they support 
learning about patients and their use of medicines.
Training and education in ethical competence should be explicitly described as a core competency 
and as part of the professionalism of the pharmacist in scientific and clinical practice.
2.6 Students must develop the knowledge and skills to critically assess scientific evidence, including 
that which is applicable to patient care and population health.
2.7
2.8
2.9
2.10
2.11
Graduate education and training for the pharmaceutical workforce should include opportunities 
for cross-disciplinary learning.
Professional communication, documentation, lifelong learning and critical thinking should be core 
competencies of pharmacists and pharmaceutical scientists. 
Students should have the ability and opportunity to learn to apply the scientific knowledge that is taught 
in the classroom in any field within the profession.
Pharmaceutical science courses will have a laboratory component to enhance students’ scientific skills.
Pharmacists should learn to work collaboratively with other healthcare professionals and scientists 
in medical, scientific and social fields.
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Cluster 4:
Cluster 3:
Foundation Training and Leadership
Recruitment of Students
Description
on the 
cluster:
Description
on the 
cluster:
4.1
3.1
4.2
3.2
4.3
4.4
4.5
Foundation training includes the process of education and leadership development for students and new 
graduates in pharmacy and the pharmaceutical sciences with a priority on developing the next generation 
of clinical, scientific, academic and professional leaders.
Recruiting students who have a profile that fits the requirements of the school and is aligned with the 
profile of pharmacists desired for the country.
There is a common scientific core for both pharmacists and pharmaceutical scientists, but the context for 
learning and teaching is different.
Admissions practices should consider the value of a diverse student body reflecting regional population 
characteristics.
Students should understand social determinants of health.
Students entering a school should have a strong scientific background, evidence of good academic 
performance and demonstrate good social and emotional skills.
Clinical competency should be assessed at relevant stages and assessment of student learning has to 
determine the extent to which students can effectively apply the knowledge taught in practice.
Assessment of student learning should include an ability for independent and self-directed learning that is 
necessary for continuing professional development after graduation.
Pharmaceutical scientists and pharmacists should gain skills in interpersonal communication and 
teamwork.
4.6 Schools should prepare students to be future mentors, supervisors, preceptors and leaders. This includes 
promoting a culture of peer support and knowledge sharing among students and encouraging students to 
mentor younger students.
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Cluster 5: Experiential Education
Description
on the 
cluster:
5.1
5.2
5.3
5.4
5.5
Experiential education programmes are where students incrementally develop their pharmacy practice 
and science skills in a wide variety of real-life settings.
Experiential education should foster development of critical thinking and problem solving processes 
relative to drug discovery and medicines use.
Students should have the opportunity to reflect on the clinical learning experience through patient case 
presentations, and development and discussions of patient notes/pharmaceutical care plans.
Pharmacy students should participate in direct patient care experiences in hospital and community 
practice settings and in other practice experiences defined by local needs for pharmacists.
Students should be provided with supervised laboratory and clinical experience throughout the 
curriculum, including demonstrations and simulations.
Students should have the opportunity to learn to apply the clinical and pharmaceutical knowledge that 
is taught in the classroom in practical settings by working under the supervision of a faculty member 
or volunteer preceptor with patients and other healthcare professionals and with other scientists.
5.6 Students should have the opportunity to participate in internships / rotations with appropriate 
supervision and guidance, based on mutually determined learning objectives.
5.7
5.8
5.9
5.10
5.11
Students should have opportunities to learn in a wide array of practice environments, including caring 
for a diverse group of patients in various cultural and health state environments.
Non-traditional settings (e.g., regulatory, industrial, non-governmental organisations) are appropriate 
environments for selective experiential education internships/rotations.
The culture of risk assessment, risk management and patient safety should be communicated clearly 
as an objective for a pharmacist when practising in different settings.
Students should demonstrate the ability and the right attitude to follow confidentiality policies.
Preceptors should be provided with opportunities to contribute to curricular decision-making, assessment 
and strategic activities.
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Cluster 6: Experiential Education
Description
on the 
cluster:
6.1
6.2
6.3
6.4
6.5
Resources and academic staff refer to equipment, finances, technology and human resources needed to 
properly prepare pharmacists and pharmaceutical scientists.
Schools should allocate resources to demonstrate opportunities and disciplines available to both 
pharmacists and pharmaceutical scientists.
Financial resources (public funding, contributions from students and other sources) should enable the 
objectives of pharmaceutical education and training to be met.
The facilities and equipment for practice and science laboratory work should be up to date, in good 
condition, and in sufficient quantity to allow learners to benefit from practical learning.
Required educational resources and supporting technologies should be available to students in the school.
A safe environment should be provided for faculty staff and learners.
6.6 Academic staff should have academic or professional experience that supports their main area of teaching 
and research.
6.7
6.8
6.9
6.10
6.11
6.12
6.13
6.14
Academic staff should demonstrate active participation in sharing their knowledge and promoting 
collaboration with colleagues in their field (and other fields) at a national and international level.
The teaching performance of academic staff should be taken into consideration for their academic 
advancement.
Academic staff should demonstrate that they continuously update their teaching material so as to ensure 
relevance to contemporary aspects and support future developments.
Active learning techniques should be used in the classroom by academic staff.
All academic staff should engage in continuing professional development that is relevant to their work 
and responsibilities.
Academic staff at schools should collaborate with preceptors and experiential learning sites to assure 
quality learning.
All academic staff should have opportunities to contribute to curricular decision-making.
The school should support and promote the academic staff, preceptors, students and administrators to 
engage in professional activities with other health sectors.
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Cluster 6: Experiential Education
6.15 The school should support and promote the participation of academic staff, preceptors, students 
and administrators in national and international activities of pharmacy and related experiences
Cluster 7: Quality Assurance
Description
on the 
cluster:
7.1
7.2
7.3
7.4
7.5
Quality assurance refers to the key aspects and mechanisms to identify opportunities for and make 
improvement in pharmacy and pharmaceutical sciences education to ensure a good, sustainable 
performance and suitable competencies of the future workforce.
A quality improvement programme should be in place at the school and university, and examples 
of specific improvement should be demonstrated periodically. 
Metrics should exist to measure, monitor, manage and improve the quality of the education and 
training provided.
Quality metrics should include feedback from students and new graduates, faculty, preceptors and key 
external stakeholders, such as employers and professional bodies. 
Policies and procedures support regular review of the curriculum and allow developments in the 
curriculum to take place in a timely manner so as to keep up with the changes in the profession, 
technology and society.
The pharmacy and pharmaceutical scientist degree programmes should be offered at a university level 
and all the experiential components (placements) in clinical, industrial and institutional settings are 
undertaken under the supervision of the school.
7.6 Competencies should be assessed throughout the curriculum, not just at the end of it, and before the 
internship period.
7.7
7.8
7.9
7.10
A formal system of quality assurance, administered by a government or an independent agency approved 
by the government, should be in place and required for all schools.
The accreditation system should use published standards that have been developed and adopted with 
broad stakeholder involvement. 
The accreditation system should use policies and procedures that ensure: evaluation by appropriately 
qualified and experienced peers; absence of conflict of interest; confidentiality; and fair and consistent 
application of standards. 
Quality improvement should always include a clear process for handling student concerns/issues/complaints 
that is transparent so that students are informed of the progress and outcome of any concern that is raised.
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Cluster 8: Continuing Professional Development
Description
on the 
cluster:
8.1
8.2
8.3
8.4
Continuing professional development (CPD) refers to building on previous education as a pharmacist 
and pharmaceutical scientist. 
CPD should apply both to those in the regulated professional practice and to those working 
in unregulated professional practice, such as academia and the pharmaceutical sciences.
All members of the pharmaceutical workforce should accept a responsibility to manage their own CPD.
Promotion of CPD should begin with students at the start of their education.
Schools should support CPD for graduated professionals to prepare them for advanced practice roles.
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PART 3
TRANSLATING OUTCOMES 
INTO ACTIONS
FIPEd builds, advocates for, and disseminates evidence-based 
guidance, consensus-based standards, tools and resources 
for educational development and quality assurance, as well 
as developing and facilitating education-related policy that 
supports advancement of the profession. 
FIPEd has developed tools that enable global action to 
improve pharmaceutical education, which are locally 
adaptable and then applied to ensure that specific country 
and regional needs are met (listed in Annex 2). FIP advocates 
for the consistent use of a needs-based approach to education 
with an emphasis on linking pharmaceutical education with 
the health needs of populations and national priorities. The FIP 
"needs-based education" model suggests that pharmaceutical 
education should be locally determined, socially accountable, 
globally connected, and quality assured to meet the given 
health needs of communities (Figure 3.1). 
3.1 Supporting FIPEd activities
FIP works as a global convener of efforts to highlight and 
champion the role of the pharmaceutical profession, as well 
as to advance pharmacy practice, pharmaceutical science and 
develop education.1 For example, joint FIP/WHO guidelines 
on good pharmacy practice describe nationally accepted 
standards for the quality of pharmacy services, 2 and the 
commitment to health outcomes through optimal medicines 
utilisation was captured in the FIP Centennial Declaration 
where “pharmacists and pharmaceutical scientists accept 
responsibility and accountability for improving global 
health and patient health outcomes by closing gaps in the 
development, distribution, and responsible use of medicines”.
 
With this declaration comes the duty to assure that the 
pharmaceutical workforce is adequately educated and trained 
to carry out its responsibility to the public and adhere to the 
accountability for bettering health. The past decade witnessed 
a longstanding history of activities demonstrating FIP’s efforts 
in leading change in workforce development and education, 
with evidence of its use at country and institutional levels, in 
alignment with global health and health workforce policies 
and strategies developed by the WHO and the United Nations.3
 
Figure 3.1: FIP Needs-based educational model.
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“This is the first time there is a global position on 
workforce development goals and principles for pharmacy 
workforce development and education.”
Associate professor Zhixiang Shi of the Chinese 
Pharmaceutical University described the legacy in the 
global conference as a historic milestone that provided an 
opportunity for the international community to come to closer 
agreement on how to educate and “cultivate a real workforce”. 
He described the implications of the conference for all 
countries and regions around the world:
“With this conference, we are getting closer and closer to 
reaching international consensus on the way forward for 
pharmacy education.”
Professor Wang Xiao-Liang and Dr Ding Lixia, vice-president 
and secretary general, respectively, of the Chinese 
Pharmaceutical Association, collectively stressed the 
effectiveness of the conference sessions in providing rationale 
and context for change by portraying the nature of future 
healthcare roles and services. Professor Wang voiced special 
support for the standards set by FIP’s three documents, with 
particular focus on the impact of the Nanjing Statements: 
“The Nanjing Statements set new global standards for 
pharmaceutical education and training and will with no 
doubt shape the development of the profession in China.”
Feedback from the participants indicates their intention on 
using the key outcomes in their own settings. Senegal’s official 
delegate, Dr Chiekhou Oumar Dia, who is also the president 
of the Pharmaceutical Council of Senegal, intends to use the 
key outcomes as a benchmark to evaluate the workforce 
development capacities offered in both educational and 
practice sectors in his country. 
Mrs Pamela Schweitzer, chief pharmacy officer of the US 
Public Health Service expressed her plans to “plant the 
seeds” by sharing the conference’s outcomes with pharmacy 
organisations as well as other health disciplines so they can 
incorporate them into their own goals. She described the 
impact of this milestone event: 
“Meeting the leaders of the world in the field of pharmacy 
was the highlight of this conference. This is the start of a 
global movement for pharmacy.”
The global conference participants expressed their shared 
enthusiasm for the progress made so far in drawing a new 
roadmap for pharmaceutical workforce transformation. 
Moving forward, FIP urges all participants, stakeholders 
and member organisations to take steps and actions 
in implementing the global vision, PWDGs and Nanjing 
Statements in their own contexts.
3.2 Engaging with the participants
The key outcomes of the global conference are a platform 
and roadmap to inform the future development of the 
pharmaceutical workforce. Their relevance relies on the 
capacity to translate the global vision, PWDGs and Nanjing 
Statements into national strategy and action plans. The 
ultimate success of these outcomes is dependent on the level 
of engagement and involvement of global pharmacy leaders, 
stakeholders and individuals. FIP is committed to maximising 
stakeholder engagement not only through public consultation 
and feedback sought before the global conference, but 
also with targeted participant engagement and validation 
activities in Nanjing. 
One of the features of the global conference’s programme 
was the high level of engagement between FIP and the 
international participants and among the participants 
themselves. Some examples of this engagement were panel 
discussions with member state representatives, workshops 
with global participants on the PWDGs, live consultation with 
country delegates on the Nanjing Statements, and media team 
interviews with a range of high-level officials and participants 
during the two-day conference. 
The interviews were conducted to gather feedback and share 
opinions from around the world about the perceived impact 
of the conference, its implications, the applicability of its 
outcomes, and the key take-home messages. Highlights from 
some of the interviews are shared below. Selected responses 
and direct quotes are also included in this report to provide a 
lasting snapshot of the general sentiments of the conference 
participants. 
High-level officials from international organisations were 
primary contributors to the conference presentations and 
discussion topics. The alignment between the PWDGs and the 
WHO’s Global Strategy have been affirmed by Jim Campbell, 
director of the WHO Health Workforce Department. He voiced 
his strong encouragement for FIP’s efforts in setting out the 
pharmaceutical workforce development agenda with these 
PWDGs:
“This is a remarkable achievement and I applaud FIP for 
its efforts in developing these Pharmaceutical Workforce 
Development Goals (PWDGs). The clear alignment with the 
World Health Organization’s human resource for health 
policies is welcome and demonstrates strong leadership 
for this critical health workforce.”
The potential implications of this global conference and its 
outcomes are “profound” according to Mrs Helen Gordon, 
chief executive of Great Britain’s Royal Pharmaceutical Society 
(RPS). As a national leadership body, the RPS intends to use the 
precedent of the PWDGs to provide guidance for its workforce 
planning strategy. Mrs Gordon urges everyone to use the 
PWDGs to take action in their own countries and highlighted 
the precedent FIP have set in holding this event: 
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This work will serve as a foundation for a dialogue to 
agree upon clear objectives for pharmaceutical workforce 
development, and strategies to achieve these objectives. Due 
consideration will be given to the identification of synergies 
and appropriate levels of engagement and collaboration with 
relevant stakeholders. 
The implementation and forward strategic plan, driven from 
the outcomes of the Nanjing conference, will directly assist 
pharmacists and pharmaceutical scientists associations 
and institutions involved in pharmaceutical workforce 
development; this programme of work will be evaluated 
and disseminated for impact of these actions at local and 
national levels. 
FIP will continue to provide clear leadership and assistance 
in the transformation of our pharmaceutical workforce 
and will monitor the outcomes of the implementation of 
the conclusions of the Global Conference on Pharmacy and 
Pharmaceutical Sciences Education on a two-year and five-
year time frame.
This is our call for action for realising the vision and goals 
for the transformation of healthcare provision and the 
health of patients.
FIP is committed to supporting the implementation of the 
Global Vision for Education and Workforce, the Pharmaceutical 
Workforce Development Goals (PWDGs) and the Nanjing 
Statements; we will lead through advocacy and engagement 
with key stakeholders and member organisations. 
The global conference showcased best practice and 
innovative approaches to professional education and 
workforce development, all aimed towards developing and 
sustaining a quality-based flexible, adaptable and competent 
pharmaceutical workforce, in alignment with the UN 
Sustainable Development Goals.e In addition, our leadership 
will align with the WHO Global Human Resources for Health 
Strategy and the recommendations and conclusions of the UN 
High-Level Commission on Health Employment and Economic 
Growth.f These approaches cover the whole workforce 
development timeline from pre-service education to advanced 
practice and specialisation. 
This comprehensive report should be considered in 
conjunction with previous FIPEd publications (see Annex 
2) so as to inform and guide strategic planning and change 
management of the pharmaceutical workforce at local, 
national and regional levels. 
FIP believes that pharmacists and pharmaceutical scientists 
associations, and importantly pharmaceutical education 
leaders, have a key role to play to translate this vision into 
a reality at local (for example, institutional), national and 
regional levels, so that the pharmaceutical workforce meets 
the public health and population needs with regards 
to pharmaceutical care and medicines expertise.
To this end, FIP is developing mechanisms to support the 
development and implementation of pharmaceutical 
workforce development strategies, integrated into the overall 
human resources for health strategies promoted by global 
and national agencies. 
Already, FIP has instigated the formation of a steering group, 
under the aegis of FIPEd, to develop needs assessments and 
gap analyses which will guide the identification of priority 
areas for action. Such group will be led by, and engage with, 
pharmacists and pharmaceutical scientists associations, 
education leaders and other influential stakeholders to 
identify indicators and impact measures in order to monitor 
progress; such indicators will be crucial for demonstrating 
relevance and the need for investment. 
FIP recognises the importance of economic indicators, 
reflecting the need for necessary resources to develop a 
sustainable workforce and to additionally quantify the return 
on investment for the economy of any country through this 
pharmaceutical healthcare workforce. This is not only a social 
accountability obligation but will also support transnational 
advocacy by providing rigorous evidence. 
PART 4
IMPLEMENTATION AND FORWARD 
STRATEGIC PLANNING AFTER NANJING
e  -   In particular, SDG 3.c. See Part 1.1
f  -   World Health Organization (WHO). Global Strategy on Human Resources 
for Health: Workforce 2030. Geneva: WHO, 2016. Available from: http://www.
who.int/hrh/resources/pub_globstrathrh-2030/en/
World Health Organization (WHO). Final report of the expert group to the High-
Level Commission on Health Employment and Economic Growth. Geneva: 
WHO, 2016. Available from: http://www.who.int/hrh/com-heeg/reports/
report-expert-group/en/
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Stimulating discussions and sharing ideas
Stimulating discussions and raising awareness of the three 
outcomes of the global conference is an important stepping-
stone to garnering attention and starting initiatives. FIP 
encourages conference participants and country delegates to 
share the key outcomes of the global conference. Organising 
discussion opportunities with the relevant stakeholders 
through conferences, a series of consultations, or workshops 
and presentations can be used to:
1. Discuss the recommendations from the global 
conference
2. Share the key messages and tenets of the Global Vision 
for Education and Workforce and use to assess or 
develop aligned national strategies 
3. Discuss the Pharmaceutical Workforce Development 
Goals and identify priority goals for development based 
on existing and future needs 
4. Discuss the Nanjing Statements on Pharmacy and 
Pharmaceutical Sciences Education and employ them a 
self-assessment tool for local pharmaceutical education 
systems
5. Develop an advocacy document to support the global 
vision and raise awareness on the need to invest in the 
national and global pharmaceutical workforce
Working together to achieve progress
Leaders from practice, education and research should 
collaborate in workforce planning efforts at a national 
level to ensure that plans include adequate attention to 
the integration of pharmacists, pharmaceutical scientists 
and pharmacy support roles to meet local health needs. 
Establishing partnerships across pharmacy sectors and 
stakeholder group is an important prerequisite to sustainable 
planning, development and implementation. 
Using existing tools and resources
National professional and scientific associations, governments 
and academic institutions are strongly encouraged to 
collaborate and use the resources developed by FIP to lead 
transformational workforce change in their own settings. 
FIPEd resources and networks can be used to implement 
educational development change. Annex 2 provides an 
extensive overview of FIPEd tools and resources, and Annex 3 
provides a comprehensive bibliography of global resources, 
tools, studies and guidelines.
The Global Conference on Pharmacy and Pharmaceutical 
Sciences Education was a milestone for developing a globally 
shared vision and roadmap for transforming pharmacy 
and pharmaceutical sciences education in the context of 
workforce development.
By drawing this roadmap in alignment with global health 
strategies and policies, FIP strives to make significant 
contributions to improving global health outcomes by 
ensuring that the pharmaceutical workforce around the world 
is appropriately educated and competent to close gaps in the 
development, distribution and responsible use of medicines.
The result of extensive planning, drafting and consultation 
processes, three key documents were presented at the 
conference and adopted by FIP: 
1. Global Vision for Education and Workforce
2. Pharmaceutical Workforce Development Goals
3. Nanjing Statements on Pharmacy and Pharmaceutical 
Sciences Education
5.1 Calls to action to all relevant stakeholders
This report outlines a way forward for workforce development 
through transforming pharmacy and pharmaceutical sciences 
education. It is intended to be used to stimulate policy action 
and discussion, and is aimed at all member organisations 
and stakeholders including professional associations, 
regulators, higher education institutions, employers, industry, 
government and individual pharmacists.
Considering the significant stride forward in establishing a 
global consensus on a shared vision, it is crucial that concrete 
steps are taken by all pharmacy stakeholders, member 
organisations, academic institutions and governments to 
implement the global vision, PWDGs and Nanjing Statements 
in their own countries and territories.
Implementing the global vision, achieving the PWDGs and 
adopting the Nanjing Statements successfully require 
stimulating interest and discussions, collaboration and 
engagement between and across all stakeholder groups, 
identifying future objectives through understanding existing 
needs, and utilising available resources and tools to facilitate 
development initiatives. A number of possible steps can be 
taken to advance the local workforce development agenda.
Analysing needs at the local level
Analysis at the local level is important to establish needs-
based objectives to meet the strategies of the global vision, 
PWDGs and Nanjing Statements. FIP encourages stakeholders 
to understand existing systems and capacities at the both the 
institutional and national levels. FIPEd tools and resources 
can be used to develop a current analysis of the situation of 
education and pharmaceutical workforce. 
PART 5
CONCLUSIONS 
AND FUTURE STEPS
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5.2 FIP’s commitment to education
Communicating and dissemination, monitoring, evaluation, 
systematic planning and comprehensive stakeholder 
engagement are clear objectives for FIP to coordinate global 
efforts for pharmaceutical workforce development fit to 
meet future pharmaceutical healthcare needs (See Figure 
5.1). It is clear, taking the evidence and advice of our global 
partners such as the WHO, that workforce development needs 
a clear and credible underpinning of workforce intelligence. 
FIP, under the aegis of FIPEd, is committed to coordinating 
these critical steps, ensuring that the voice of experts, 
practitioners and leaders are all taken into account; it will 
not be possible to produce aggregate global change without 
direct local involvement and there has to be a commitment to 
find and disseminate best practice to avoid duplication and 
reinvention.
Figure 5.1: Strategic Planning Framework.
The global conference was a historic moment for the 
pharmaceutical profession, but it is now time to turn this 
moment into momentum to set in motion a global movement 
of transformational change for the pharmaceutical workforce 
to improve global health.
Strategy and Stewardship
3 & 5 year planning
FIP 
Boards & Education
Communication 
Feedback & Symposia
Member Organisations
Progress & Evaluation 
FIP Expert Groups
FIP Expert 
& Partner Groups
Continuous renewal of workforce intelligence
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ANNEX 1. LIST OF PARTICIPATING 
COUNTRIES AND TERRITORIES
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Quality Assurance
The Framework is offered primarily as a 
tool — to be used in whole or in part — to 
facilitate the establishment of systems of 
quality assurance in countries where no such 
formal systems exist or for improvement of 
existing systems. Where regional similarities 
and collaborations exist, the Framework 
may also be applied at a regional rather than 
national level. Where resources or other 
constraints limit the immediate application 
of some of the principles outlined in the 
Framework, it is hoped that the document 
can serve as a “road map” for the future. 
http://bit.ly/29zgrSc
Workforce Intelligence
The reports have set out to recognise the 
major challenges facing both the profession 
and global healthcare systems. The quality, 
scope and capability of the workforce are 
dependent on the nature of initial and life 
long professional development curricula, and 
the quality of available practitioner support 
and recognition structures. 
http://bit.ly/29kipF8
• Prerequisites for Quality Assurance    
   in Pharmacy Education
• Quality Criteria and Quality  
   Indicators for Pharmacy Education
• The Quality Assurance Agency
• Glossary 
2006
• Data from 17 countries and  
   territories
• Case studies from 7 countries and  
   territories [Australia, Canada,  
   Ireland, Ghana, Kenya, New  
   Zealand, United Kingdom]
2009
• Data from 56 countries and  
   territories
• Case studies from 7 countries and  
   territories [Australia, Canada, Great  
   Britain, Kenya, Jordan, Uruguay,  
   Vietnam]
• Needs-based Educational Model
• WHO chapter
2012
• Data from 90 countries and  
   territories
• Case studies from 9 countries and  
   territories [Afghanistan, Costa Rica,  
   Ghana, Great Britain, Japan, Pacific  
   Islands, Singapore, South Africa,  
   Tanzania]
• WHO chapter
2015
• Trends analysis conducted with  
   data from the workforce reports  
   (2006, 2009 and 2012)
• Data from 51 countries and  
   territories
• Higher Education  
   Institutions
• Professional   
   Associations
• Regulators
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
• Industry
FIPEd Tools/Description Concept/Content Aimed for:
ANNEX 2. 
OVERVIEW OF FIPEd TOOLS 
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FIP UNESCO-UNITWIN Global Pharmacy 
Education Development Network
UNITWIN/Cooperation Programme on 
Global Pharmacy Education (GPhED) was 
created within the framework of the UNESCO 
-UNITWIN Programme to fulfil objectives such 
as sharing best educational practice between 
and among education institutions and other 
education providers across borders.
Global Competency Framework (GbCF)
Promotes the development of knowledge, 
skills, attitudes and behaviours that an 
individual develops through education, 
training, development and experience as 
means to create a capable practitioner 
workforce in all healthcare professions.  
The GbCF v1 is divided in 4 clusters/areas 
of practice, 20 competencies and 100 
behavioural competencies. It is intended to 
act as a mapping tool and can be adapted 
according to the country or local needs. 
These competencies improve therapeutic 
outcomes, patients’ quality of life, scientific 
advancement and enhancement of public 
health imperatives. 
http://bit.ly/1TIMWe3
Pharmacy Support Workforce
Pharmacy technicians and support staff, 
pharmacists and individuals who work 
with the pharmacy support workforce in 
education, practice, regulation, development 
and promotion explore how to educate, 
develop and fully utilise the pharmacy 
support workforce within the healthcare 
system. The discussions and debate during 
this one-and-a-half-day symposium focus on 
areas of critical importance for sustainability 
of healthcare programmes, with a focus on 
global initiatives that support and strengthen 
the work of mid-level cadres in the delivery of 
pharmacy services.
Global Education Report 
Academic and Institutional Capacity Domain
FIPEd Global Education report provides a 
baseline on the current status, transformation 
and scaling up of pharmacy and 
pharmaceutical sciences education globally.
http://bit.ly/29qvMko
• Network of Schools
• Centres of Excellence:
   Global – 1st one, African Centre of  
   Excellence
   [Founding partners: Ghana,  
   Uganda, Nigeria, Namibia, Zambia;  
   Malawi]
The GbCF contains:
• The drivers for the development of  
   a global competency framework.
• The process of the GbCF   
   development.
• The concept of the GbCF   
   competencies. 
• Guidance on how to use the GbCF.
• The GbCF framework.
• The domain initiated an annual  
   FIP Global Pharmacy Technician  
   and Pharmacy Support Workforce  
   Symposium in 2012, which has been  
   the basis for increased sharing and  
   practice development.
• Data from 109 countries 
   and territories
• Case studies from 14 countries  
   and territories [Chile, Great Britain,  
   Japan, Jordan, Malaysia, Namibia,  
   Philippines, Portugal, Saudi Arabia,  
   Switzerland, Thailand, UAE, USA,  
   Zimbabwe]
• Higher Education  
   Institutions
• Educators
• Professional   
   Associations
• Regulators
• Higher Education           
   Institutions
• Employers
• Industry
• CPD/CE providers
• Individual   
   Pharmacists
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
• Employers
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
FIPEd Tools/Description Concept/Content Aimed for:
42 Transforming pharmacy and pharmaceutical sciences education
Continuing Professional Development/
Continuing Education (CPD/CE) Report
CPD is “the responsibility of individual 
pharmacists for systematic maintenance, 
development and broadening of knowledge, 
skills and attitudes, to ensure continuing 
competence as a professional, throughout 
their careers”. An ongoing cyclical process 
involving: self-appraisal, developing a 
personal learning plan, taking action 
or implementing the learning plan, and 
evaluation. The report has presented the 
current trends and activities with regard 
to professional development and lifelong 
learning across countries and territories 
globally.
http://bit.ly/29vvRUE
Interprofessional Education (IPE) Report
The report presents a collection of case 
studies and examples that reflect innovation 
and creativity centred on IPE. These case 
studies highlight diverse approaches 
and show that IPE is becoming a more 
mainstream education activity for students, 
trainees and practitioners worldwide. Still, 
FIPEd acknowledges the limited evidence and 
evaluation regarding the long-term impact of 
IPE initiatives. This suggests that it is needed 
to continue to follow projects such as those 
highlighted here and also encourage stronger 
interprofessional dialogue about monitoring 
and evaluation methods.
http://bit.ly/29qUuUg
PharmAcademy
PharmAcademy is the go-to place for 
pharmacy educators worldwide to connect, 
and share knowledge and resources. It 
is a community site designed to connect 
pharmacy educators globally.
http://pharmacademy.org/
Pharmacy Education Journal
Hosted by PharmAcademy, the journal is a 
peer-reviewed publication, allowing free 
submission and access to over 500 articles 
around pharmacy and pharmacy education 
workforce. 14,000 journal article donwloads 
since August 2015. 
http://bit.ly/2a1pdbC
• Data from 66 countries and  
   territories
• Case studies from 9 countries  
   and territories [Australia, Canada,  
   Croatia, Japan, Namibia, New  
   Zealand, Northern Ireland, Oman  
   and USA]
• A WHO case study.
• Case studies from 12 regional,  
   national and institutional-level  
   examples and initiatives   
   [Professional bodies, Accreditation  
   agencies, Student organisations,  
   Australia, China, Kenya, Lebanon,  
   Malaysia, Namibia, Philippines, UK  
   (Great Britain), Uruguay]
PharmAcademy, is an online platform 
where is possible to:
• Learn from others with 
   more experience.
• Teach and guide others with 
   less experience.
• Publish stories and news items 
   of interest to the community.
• Join or create groups of peers that  
   share common interests.
• Participate in the development 
   of pharmacy education.
• Publish on the Pharmacy Education 
   Journal.
• Professional   
   Associations
• Regulators
• Higher Education  
   Institutions
• Employers
• Industry
• Other providers 
   of CPD/CE
• Professional   
   Associations
• Higher education   
   institutions
• Employers
• Educators
• Individual    
   Pharmacists
• Authors
FIPEd Tools/Description Concept/Content Aimed for:
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Advanced Practice and Specialisations Report 
This report is the most comprehensive 
collection of data and evidence that relates 
to practitioner advancement of practice and 
policy, and maps out a wide range of national 
initiatives worldwide. This report should be 
viewed as a first attempt to map out global 
trends and will stimulate further reportage 
and analysis as engagement in this practice 
continues to progress.
http://bit.ly/29zgP3j
Transforming Our Workforce
Transforming Our Workforce is a enabling 
document designed to have a long half-life. 
It describes evidence-based and tested tools 
and mechanisms whereby leadership bodies 
and policy-makers can gain traction for 
advancing the pharmacy workforce. 
http://bit.ly/29kipF8
• Data from 48 countries 
   and territories 
• Case studies from 17 country and  
   territories [Argentina, Australia,  
   Canada, China, India, Ireland, Japan,  
   Malaysia, New Zealand, Philippines,  
   Portugal, Singapore, South Africa,  
   Spain, Switzerland, United Kingdom 
   (Great Britain), USA]
• Development case studies of the 10  
   FIPEd tools
• Case studies from 14 national and  
   institutional-level examples and  
   initiatives [Australia, Chile, Croatia,  
   India, Jordan, Malawi, New Zealand,  
   Kenya, Serbia, Spain, Thailand, UK  
   (Great Britain)]
• Professional      
   Associations and       
   Regulatory 
   Authorities
• Employers
• Individual   
   Pharmacists
All Stakeholders
• Professional      
   Associations
• Regulators
• Higher Education     
   Institutions
• Employers
• Industry
• Individual   
   Pharmacists
FIPEd Tools/Description Concept/Content Aimed for:
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